The impact of SARS-CoV-2 variants on IBD management

Lancet Gastroenterol Hepatol. 2021 May;6(5):343-344. doi: 10.1016/S2468-1253(21)00075-3. Epub 2021 Mar 10.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adaptive Immunity
  • COVID-19 Vaccines / therapeutic use*
  • COVID-19* / epidemiology
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Humans
  • Immunogenicity, Vaccine
  • Immunosuppressive Agents / therapeutic use*
  • Inflammatory Bowel Diseases* / epidemiology
  • Inflammatory Bowel Diseases* / therapy
  • Patient Care / methods
  • SARS-CoV-2 / genetics*
  • SARS-CoV-2 / pathogenicity
  • United Kingdom

Substances

  • COVID-19 Vaccines
  • Immunosuppressive Agents